Orchard Therapeutics plc
Orchard Therapeutics plc, a pioneering gene therapy company headquartered in Great Britain, focuses on transforming the lives of patients with rare genetic disorders. Founded in 2015, Orchard has rapidly established itself as a leader in the biotechnology industry, particularly in the development of innovative gene therapies that address unmet medical needs. With a strong operational presence in Europe and the United States, Orchard Therapeutics is renowned for its unique approach to ex vivo gene therapy, which involves modifying a patient's own cells to treat diseases. The company’s flagship products, including Libmeldy, exemplify its commitment to delivering transformative treatments. Orchard's notable achievements include securing regulatory approvals and forming strategic partnerships, solidifying its position as a key player in the gene therapy landscape.
DitchCarbon Score
How does Orchard Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orchard Therapeutics plc's score of 66 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orchard Therapeutics plc, headquartered in Great Britain, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Kyowa Kirin Co., Ltd., which may influence its climate commitments and initiatives. While Orchard Therapeutics has not set its own reduction targets, it is aligned with the sustainability efforts of its parent company, Kyowa Kirin Co., Ltd. This includes participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Kyowa Kirin at a level 1 relationship. Additionally, Orchard Therapeutics is indirectly linked to Kirin Holdings Company, Limited, which is involved in the RE100 and other climate initiatives at a level 2 cascade. As of now, Orchard Therapeutics plc has not publicly committed to specific carbon reduction targets or climate pledges. The company’s climate strategy may evolve as it aligns more closely with the sustainability frameworks established by its parent organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 17,244,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 34,687,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orchard Therapeutics plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
